|Articles|February 21, 2012

HIPAA and Mental Health Treatment For Adolescents

HIPAA and privacy: To what extent should parents involve themselves in the mental health treatment of an adolescent?

Regarding privacy concerns and involvement in mental health treatment for family members, what do you say?

For more information on health infomation privacy, see

Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security Rules

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

An Update on the Harms of Social Media on Teen Mental Health: Meta Settles for $18 Billion

ByLeah Kuntz

August 28th 2026

Psychiatry and the Treatment of Stuttering: A Blossoming Partnership

ByMike Hennessy Jr

August 11th 2026

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

ByGerald A. Maguire, MD,Heidi Anne Duerr, MPH,Shahriar SheikhBahaei, PhD,Yoshikazu Kikuchi, MD, PhD,Lisa LaSalle PhD, CCC-SLP,Thomas J. Valente, MD,Anelise Junqueira Bohne, PhD, SLP,Tiago Proença dos Santos, MD,Gonçalo Leal, SLP,Devin Binder, MD, PhD,Gustavo Alva, MD, DFAPA,Greg Mattingly, MD

August 10th 2026

Attachment-Based Therapy in Adolescent Substance Users: A Meta-Synthesis of Emotional Isolation and Avoidant Attachment Patterns

ByBahareh Mahooti

July 28th 2026

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

ByGustavo Alva, MD, DFAPA,Ann Childress, MD

June 26th 2026

Latest CME

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

HIPAA and Mental Health Treatment For Adolescents

Related Content

An Update on the Harms of Social Media on Teen Mental Health: Meta Settles for $18 Billion

Psychiatry and the Treatment of Stuttering: A Blossoming Partnership

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

Attachment-Based Therapy in Adolescent Substance Users: A Meta-Synthesis of Emotional Isolation and Avoidant Attachment Patterns

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

Latest CME

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Trending on Psychiatric Times

Insanity Trials and The Court of Popular Opinion

Phase 2 Trial of Bezisterim for Neurological Symptoms of Long COVID: Treatment Phase Completed

Novel Serotonergic Agonist, HLP003, Targets the Adjunctive MDD Treatment Gap

August 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News

International Overdose Awareness Day Marks 25th Year as US Overdose Deaths Decline Yet Remain High